Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* History and subjective symptoms of cat dander allergy including cat specific allergic rhinitis~* Age 18 to 65 years~* Positive reaction to at least one concentration of cat dander allergen in skin prick test, intradermal provocation test and nasal provocation test~Exclusion criteria:~* Chronic infectious disease~* Acute infections~* Episode of non-allergic rhinitis within the last 4 weeks~* Use of allergen known to predict anaphylactic reactions~* Treatment with any other investigational drug within 3 months before trial entry~* Vaccination within the last week~* Nasal surgery within the last 8 weeks~* Progressive fatal disease~* Drug or alcohol abuse within the last 5 years~* Cat ownership~* A history of significant cardiac insufficiency (NYHA stage III-IV)~* Coexisting severe disease, e.g. cardiovascular diseases~* Acute or history of obstructive respiratory insufficiency ( FEV1 \<70%)~* Hepatic insufficiency~* Relevant anaemia (as judged by investigator)~* Blood donation within the last 30 days or intended blood donation (during the study or 30 days after participation)~* Pregnancy or breast feeding~* Sexually active woman of childbearing potential not actively practicing birth control by using a medically accepted device or therapy~* Lack of compliance or other sililar reason, that the investigator believes, precludes satisfactory participation in the study~* Systemic glucocorticoid therapy~* Allergic asthma and chronic medication with steroids at doses exceeding 200ug/day Treatment with ATII antagonists, B-blocker, ACE inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Study drug
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).